We previously observed that disruption of FK506-binding protein 12.6 (FKBP12.6) gene resulted in cardiac hypertrophy in male mice. Studies showed that overexpression of FKBP12.6 attenuated thoracic aortic constriction (TAC)-induced cardiac hypertrophy in mice, whereas the adenovirus-mediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes, indicating that the role of FKBP12.6 in cardiac hypertrophy is still controversial. In this study, we aimed to investigate the roles and mechanisms of FKBP12.6 in angiotensin II (AngII)-induced cardiac hypertrophy using various transgenic mouse models in vivo and in vitro. FKBP12.6 knockout (FKBP12.6 À/À ) mice and cardiac-specific FKBP12.6 overexpressing (FKBP12.6 TG) mice were infused with AngII (1500 ng/kg/min) for 14 days subcutaneously by implantation of an osmotic mini-pump. The results
| INTRODUCTION
Cardiac hypertrophy is characterized with myocardial cell hypertrophy, extracellular matrix increase and myocardial interstitial cell proliferation, and it is a compensatory response to variety of cardiovascular diseases such as high blood pressure, heart valve disease and myocarditis. Many factors including mechanical stress and neurohumoural stimulation induce cardiac hypertrophy. 1 Among them, angiotensin II (AngII), a degraded peptide from the renin-angiotensin system, is one of the most powerful stimuli in inducing cardiac hypertrophy and fibrosis. 2 In patients with an excessive activated RAS (rennin-angiotensin system) or enhanced responsiveness to AngII, the inappropriate remodelling and vascular diseases were initiated. 3 The roles of AngII in cardiovascular system are mainly mediated by AT1R activation via complex interacting signalling pathways involving primary stimulation of phospholipase C (PLC), Ca 2+ mobilization, secondary activation of non-receptor tyrosine kinase Src, phosphatidylinositol 3-kinase (PI3-kinase)/protein kinase B (AKT) and mitogenactivated protein kinase. [3] [4] [5] It has been reported that AngII-activated Ca 2+ signalling pathway initiated the progress of cardiomyocyte hypertrophy. 4, 6 AngII induces Ca 2+ influx via G protein-mediated activation of PLC that leads to phosphatidylinositol hydrolysis and formation of inositol trisphosphate (IP3) and diacylglycerol (DAG), in which IP3 binds to its receptor on sarcoplasmic reticulum (SR), opening the channel that allows calcium efflux into the cytoplasm. 3, 5 FK506-binding protein 12.6 (FKBP12.6), a member of the FKBPs family, has 85% amino acid sequence identity with FKBP12 7 and is selectively associated with cardiac ryanodine receptor (RyR2) which is predominantly expressed in heart and plays a crucial role in the regulation of Ca 2+ release from cardiac SR. [8] [9] [10] It has been reported that cyclic ADP Ribose (cADPR) induces a sustained Ca 2+ increase by dissociating FKBP12.6 from RyR2 of the cardiac SR via calciuminduced calcium release (CICR), 4 which further activate Ca 2+ -dependent signalling pathways such as the calcineurin/cardiac form of nuclear factor of activated T cells 4 (NFATc4) and the calmodulin kinaseII (CaMKII)/MEF-2 pathways to lead to cardiac hypertrophy. 3, 5, 11 NFATc4 transcriptional factor, a key molecule in cardiac hypertrophy induction, serves as a down target of calcineurin and
Glycogen synthase kinase 3b (GSK3b), in which its transcriptional activity was regulated by its nucleus-cytoplasmic shuttling. 12 We have previously showed that disruption of the FKBP12.6
gene resulted in cardiac hypertrophy in male mice, 13 and cardiacspecific overexpression of FKBP12.6 that was driven by the a-MHC promoter was able to rescue the cardiac hypertrophy and abnormal calcium release in FKBP12.6 knockout (FKBP12.6
À/À ) mice. 14 Studies showed that cardiac-specific overexpressing FKBP12.6 in mice blunted thoracic aortic constriction (TAC)-induced maladaptive left ventricular remodelling and protected against catecholamine-induced ventricular tachycardia after TAC. 15, 16 The cardiac FKBP12.6 overexpression also reduced the molecular signature of left ventricular hypertrophy (LVH) and the mortality in TAC male mice. 17 These results suggest that FKBP12.6 may protect heart from cardiac hypertrophy. However, a study showed that the adenovirusmediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes, 18 indicating that the role of FKBP12.6 in cardiac hypertrophy is still controversial.
Several lines of evidence suggest that the renin-angiotensin system and AngII may contribute to cardiac hypertrophy in response to pressure overload. 19, 20 However, it has been observed that there were disparate effects of ACE inhibitors or disruption of AT1 receptor on the development of LV hypertrophy after pressure overload.
These results indicated that it is not clear whether AngII plays a critical role in the development of cardiac hypertrophy induced by pressure overload. [21] [22] [23] [24] [25] Therefore, it is still necessary to clarify the role of FKBP12.6 in AngII-induced cardiac hypertrophy.
This study aimed to clarify whether FKBP12.6 protects hearts from the AngII-induced cardiac hypertrophy and to elucidate the mechanisms of FKBP12.6 in pathological cardiac hypertrophy.
FKBP12.6 À/À mice and the cardiac-specific FKBP12.6 overexpressing mice were used for producing the mouse models of the pathological cardiac hypertrophy with AngII stimulation. In addition, an H9c2 cell line with stable expressing FKBP12.6 exogenously was constructed for elucidating the mechanisms of the protection of FKBP12.6 in AngII-induced cellular hypertrophy.
| MATERIALS AND METHODS

| Animal models and echocardiography
Two-month-old male mice including FKBP12.6 À/À mice, 13 cardiacspecific FKBP12.6 overexpressing transgenic (FKBP12.6 TG) mice 14 and age-/genetic-matched wild-type (WT) mice were used in this study. The mice with the congenetic background of C57/B6 were prepared by backcrossing both FKBP12.6 À/À and FKBP12.6 TG mice with WT mice of C57/B6 genetic background for more than 6 generations, and the WT littermates were used as controls. The mice were anaesthetized with 2.5% 2,2,2-tribromoethanol (Avertin, Sigma Chemical Co) by intraperitoneal injection (15 lL/g), and each mouse was infused with AngII (1500 ng/kg/min) or saline for 14 days subcutaneously by implantation of an osmotic mini-pump (ALZET Model 1002D; DURECT, Cupertino, CA, USA) through a small pocket made in the skin between the scapulae. The primer pairs (forward, reverse) were used in this study as fol-
| Western blot analysis
Hearts were dissected and homogenized in RIPA-buffer (10 lL/mg) containing proteinase inhibitors cocktail (Roche Diagnostics, Mannheim, Germany), the cells were also lysed with RIPA-buffer. The cytoplasmic and nuclear proteins were isolated using NE-PER 
| Calcium assay
| Data analysis
Independent two-sample t-test and two-way ANOVA were applied to determine statistical significance. Differences were considered to be statistically significant when P < .05.
3 | RESULTS
| FKBP12.6 deficiency aggravates AngII-induced cardiac hypertrophy in vivo
To investigate the effects of FKBP12.6 on cardiac hypertrophy, we first examined the expressions of FKPB12.6 in the heart of WT mice in response to AngII stimulation. As showed in Figure 1A , the mRNA levels of FKBP12.6 were down-regulated by 29% in hearts of WT mice after AngII infusion for 14 days, suggesting that FKBP12.6 might play a critical role in AngII-induced cardiac hypertrophy. Given that the expression of FKBP12.6 was decreased in the hearts of WT mice after AngII stimulation, the effects of FKBP12.6 deficiency on AngII-induced cardiac hypertrophy were further investigated using FKBP12.6 À/À mice. As showed in Figure 1B , AngII infusion for 14 days significantly increased the HW/BW ratio in FKBP12.6 À/À mice by 37.9% compared with the 27.2% augment in WT hearts, due to the heart weights of FKBP12.6 À/À mice were significantly increased compared with the WT hearts, while the body weights of both mice were not influenced by AngII stimulation (Table S1 ), indicating that FKBP12.6 might protect heart from AngII-induced cardiac hypertrophy. Therefore, we further checked the size of cardiomyocytes and the expressions of hypertrophic genes after AngII stimulation. As showed in Figure 1C ,D, the cross-sectional areas of cardiomyocytes in FKBP12.6 À/À mice were significantly augmented compared to WT mice after Ang II infusion. Consistent with the above result, disruption of FKBP12.6 significantly increased AngIIinduced expressions of ANF and BNP which served as the hallmarks of cardiac hypertrophy ( Figure 1E,F) . In addition, although we observed that AngII stimulation markedly promoted the fibrosis of cardiac tissues in WT mice, there was no significant aggravation of the fibrosis in the null mice ( Figure S1 ). To examine the effects of FKBP12.6 deficiency on cardiac functions after AngII infusion, echocardiography was measured for each mouse. As analysed in of WT hearts. However, FKBP12.6 overexpression seems no effect on AngII-induced fibrosis ( Figure S2 ). Consistent with the above studies, the results of echocardiography (Table S2 ) also showed that FKBP12.6 TG mice protected heart from AngII-induced hypertrophy, seen as the decreased heart weight, thickness of IVSD, IVSS and LV mass. All the results indicated that overexpression of FKBP12.6 protected heart from AngII-induced cardiac hypertrophy in mice. Figure 5C -E) and NFATc4 (Figure S3) . Next, to further define the mechanism of calcineurin signalling pathway, the nuclear translocation of the cardiac form of NFAT (NFATc4) in the cells were determined. As showed in Figure 5F -H, overexpression of FKBP12.6 in H9c2 cells markedly inhibited the AngII-induced NFATc4 nuclear translocation (P < .05, n = 3).
3.6 | Overexpression of FKBP12.6 significantly protects cardiomyocytes from the AngII-induced hypertrophy through inhibiting the Ca 2+ /CaMKII, AKT/
GSK3b and AKT/mTOR signalling pathways in H9c2 cells
To further elucidate the mechanisms of the protection of FKBP12.6
on AngII-induced cardiac hypertrophy, the effects of overexpressing F I G U R E 3 Cardiac-specific overexpression of FKBP12.6 markedly inhibited AngII-induced elevation of calcineurin, CaMKII and AKT activities in mice. The expressions of calcineurin (CaN) and MCIP1.4 (a highly sensitive readout for calcineurin activity) were detected by Western blot (A) and quantitatively determined by density analysis (B,C) in hearts from FKBP12.6 TG and WT mice that were subjected to 14 days of AngII or saline infusion. The expressions of the total or phosphorylated proteins including CaMKII, AKT and mTOR were detected by Western blot analysis (D-F) and the protein expression of p-CaMKII (G), p-AKT (H) and p-mTOR (I) was normalized to total CaMKII, AKT and mTOR in the hearts of the mice. GAPDH expression was used as loading control. The data represent the mean AE SEM, n = 5, *P < .05 for FKBP12.6 TG vs WT mice and 
| Overexpression of FKBP12.6 attenuates
AngII-induced myocardial apoptosis in H9c2 cells
It has been reported that AngII promotes ROS generation and calcium overload. Severe oxidative stress could lead to the apoptosis of myocardial cells and subsequently activate the TGFb-Smad pro-fibrosis signalling pathway. 28, 29 As showed in Figure 7A 
| DISCUSSION
In vivo studies showed that the cardiac-specific overexpression of FKBP12.6 protected heart from cardiac hypertrophy. [15] [16] [17] In contrast, respectively. The NFATc4 protein levels in cytosolic and nuclear fractions were analysed by Western blot (F). TATA-binding protein (TBP), a nuclear protein marker, and Tubulin, a cytosolic protein marker, were used as an internal control, respectively. The contents of NFATc4 protein in nuclei (G) and cytosole (H) were quantitatively determined by density analysis. The data represent the mean AE SEM from three independent experiments, *P < .05 for FKBP12.6-overexpression vs Flag-control and # P < .05, ## P < .01 for PBS vs AngII groups a few studies showed that the increased FKBP12.6 expression might be associated with some cardiovascular diseases, suggesting that the heart may employ FKBP12.6 up-regulation as an adaptive response to ameliorate cardiac dysfunction. 30 However, an in vitro study showed that the adenovirus-mediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes due to the activation of ERK1/2, 18 indicating that the role of FKBP12.6 in cardiac hypertrophy is still unclear. In the present study, using both overexpression and knockout mouse and overexpression cell models, we first time demonstrated that FKBP12.6 protects hearts from AngII-induced hypertrophy in vivo and in vitro, seen as lack of FKBP12.6 gene markedly aggravate AngII-induced cardiac hypertrophy, whereas cardiac-specific overexpression of FKBP12.6 prevents the hypertrophic response to AngII. Moreover, we observed that there was no change in the cardiomyocyte sizes between the Flag-control (Flag) and overexpression of FKBP12.6 (F12.6) H9c2 cells. We also found FKBP12.6 overexpression did not promote the activation of ERK1/2 as reported in adenovirusmediated overexpression of FKBP12.6, 18 and it did not prevent the activation of ERK1/2 induced by AngII neither ( Figure S4) . Therefore, the different results may be due to using different sources of cardiomyocytes or different approaches to explore the role of the induction of foetal heart genes. 31 H9c2 cells are rat heart embryonic myoblasts, with skeletal muscle properties, which terminally differentiate by fusing and forming multinucleated myotubes. Cardiomyocytes isolated from embryonic or neonatal rat hearts spread quite readily on the culture plate in 1% horse serum. 32 We cultured H9c2 cells in 2% serum medium for a short time (no more than 48 hours) and at the end of our experiments, we did not observe that the cells differentiate into myocytes/myotubes. We showed that the protection of FKBP12.6 on the AngII-induced cell hypertrophy was associated with inhibitions of the Ca 2+ -mediated calcineurin/NFATc4, CaMKII/MEF-2, and AKT/mTOR, AKT/GSK3b/NFATc4 signalling pathways.
Many pieces of evidences suggest that AngII elevates blood pressure, which in turn promotes haemodynamic overload. The adaptation of the heart to this overload is to alter cardiac protein expression and substantial cardiac remodeling. 2, 3 In addition to vasoconstrictor effects, AngII also exerts direct growth-promoting effects on cardiac tissues, resulting in myocardial hypertrophy and mechanical dysfunction independently on blood pressure elevation. 3, [33] [34] [35] [36] Both physiological and pathological cardiac hypertrophies are associated with elevation of cardiomyocyte Ca 2+ levels, 37 whereas the The quantitative expressions of total and phosphoryated CaMKII, AKT and GSK3b protein were performed by density analysis, and the protein expression of p-CaMKII (B), p-AKT (C), p-GSK3b (E) and p-mTOR (F) was normalized to total CaMKII, AKT, GSK3b and mTOR. GAPDH was used as the loading controls. The data represent the mean AE SEM from three independent experiments, *P < .05, ***P < .001 for FKBP12. and CaMKII/MEF-2 signalling pathways. 38, 39 Activated calcineurin is both necessary and sufficient to induce cardiac hypertrophy in vitro and in vivo, cardiac-specific overexpression of calcineurin in mice showed a dramatic increase in heart sizes.
Increased activity of calcineurin results in dephosphorylation of NFATc4, and subsequently induces transcription of foetal cardiac genes via a combinatorial mechanism involving its direct interaction with GATA4. 40 Our results showed that overexpression of FKBP12.6
significantly inhibited AngII-induced calcineurin activities and , and the Bax/Bcl2 ratios were quantitatively determined by density analysis (F). GAPDH was used as an internal control. The data represent the mean AE SEM from three independent experiments, *P < .05 for FKBP12.6-overexpression vs Flagcontrol and # P < .05 for PBS vs AngII group, NS represents no significance pathway. CaMKII induces phosphorylation of the class II histone deacetylase 4 (HDAC4), which in turn dissociates from the MEF-2 transcription factor, and translocates to the cytoplasm from the nucleus, leading to the activation of MEF-2, which is sufficient to promote pathological hypertrophy. 38 In our study, overexpression of FKBP12.6 inhibited the AngII-induced phosphorylation of CaMKII (indicative of CaMKII activation) in heart or in H9c2 cells, suggesting that overexpression of FKBP12.6 prevents hearts or H9c2 cells from AngII-induced hypertrophy by suppressing the activation of CaMKII.
Recent studies showed that the mTOR signalling pathway plays a major role in modulating structural and functional adaptation of the heart to both haemodynamic stress and non-haemodynamic factors. 41 Rapamycin acts by irreversibly binding FKBP12 and FKBP12.6, which inhibits mTORC1 assembly, diminished hypertrophic responses to the Gq-protein-coupled receptor agonists AngII. 42 AKT, a member of the AKT/PKG/PKC family of serine/threonine kinases, is known to function both upstream as an activator of mTOR and downstream as a phosphorylation target of mTOR at S473. 43 Our results showed that overexpression of FKBP12.6
appears to be able to prevent AngII-induced the increases of the phosphorylation-AKT and phosphorylation-mTOR and then inhibited the progress of cardiac hypertrophy induced by AngII.
GSK3b, as an inhibitor of hypertrophic signalling in the intact myocardium, is a ubiquitous serine-threonine protein kinase which phosphorylates NFAT proteins and antagonizes the action of calcineurin by promoting NFAT nuclear export, and the activity of GSK3b is regulated by the phosphorylation status of serine-9. AKT has been shown to phosphorylate serine-9 of GSK3b, thereby inactivating the enzyme. 12 As we expected, the phosphorylations of AKT and GSK3b were increased in response to stimulation of AngII in Flag-control cells, indicating that the AngII-induced decreased activity of GSK3b result in NFATc4 accumulated in the nuclear and promoted the development of cardiac hypertrophy, whereas FKBP12.6 overexpression significantly ameliorated such alterations.
These results suggested that inhibition of FKBP12.6 overexpression on the AKT/GSK3b/NFATc4 signalling pathway further enhances the protection of the protein on AngII-induced cardiomyocyte hypertrophy.
Evidences have showed that AngII-induced oxidative stress preserve an important role in pathological hypertrophy. AngII activates membrane NAD(P)H oxidases, such as superoxide and hydrogen peroxide (H 2 O 2 ) to produce ROS, which is involved in the pleiotropic effects of AngII. 3 ROS generation may further induce cell apoptosis, which is involved in antiapoptotic Bcl2 and the pro-apoptotic Bax. 44 The apoptotic cells induced by AngII are then replaced by excessive collagen fibrosis, and reduced capillary density increased oxygen diffusion distances leading to myocardial ischaemia, and finally contribute to the transition from hypertrophy to failure. 28 As showed in our study, overexpression of FKBP12.6 significantly reduced the apoptosis cells and inhibited intracellular Bax/Bcl-2 ratio, but almost has no effects on AngII-induced ROS generation, suggesting that overexpression of FKBP12.6 protects heart from hypertrophy partially through inhibiting apoptosis induced by AngII.
In addition, AngII-induced oxidative stress and cell injury were reported to promote cardiac remodelling through TGFb1 signalling pathway. 45 AngII and TGFb1 do not act independently from one another but rather act as part of a network that promotes cardiac remodeling. 46 TGFb, a potent stimulator of collagen production by cardiac fibroblasts, acts downstream of AngII and promotes myocyte growth and fibrosis. 46 In the canonical pathway, Smad2/3 is phosphorylated by TGFb receptor type 1. There is growing evidence in the literature to suggest that Smad2 is not a mediator of cardiac fibrosis, whereas Smad3 regulates of the secretory phenotype of myofibroblasts and has a detrimental effect on myocardial fibrosis. 46, 47 We showed that FKBP12.6 overexpression did minor things in inhibiting the increased level of TGFb1 expression, and phosphorylation-Smad3 induced by AngII. Additionally, it is reported that the TGFb/Smad pathway activates the transcription of several key fibrotic genes through the ERK1/2 pathway. 29 ERK1/2 has been implicated as the regulators of cardiac hypertrophy in both cell culture and genetically modified mouse models. However, genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo, 48 and ERK1/2 pathway is reported to activate the transcription of several key fibrotic genes through TGFb-Smad pathway, 29 indicating that ERK1/2 may not be necessary for cardiac hypertrophy but play an important role in promoting fibrosis. Our results showed that although FKBP12.6 overexpression did not promote the activation of ERK1/2 as reported in adenovirus-mediated overexpression of FKBP12.6, 18 it did not prevent the activation of ERK1/2 induced by AngII neither. Therefore, we speculated that FKBP12.6 overexpression is not sufficient to inhibit the ERK1/2-TGFb1-Smad pathway for protecting hearts from AngII-induced fibrosis.
| CONCLUSION
Our results demonstrated that FKBP12.6 protects heart from AngII- Medicine for echocardiography measurements.
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